Octagon Capital Advisors LP I Mab Transaction History

Octagon Capital Advisors LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$8.27 - $18.43 $7.03 Million - $15.7 Million	-849,815 Reduced 80.96%	199,876 $2.26 Million
Q4 2021 Feb 14, 2022	BUY	$45.28 - $74.5 $12.9 Million - $21.2 Million	285,230 Added 37.31%	1,049,691 $49.7 Million
Q3 2021 Nov 15, 2021	SELL	$57.18 - $84.43 $10.2 Million - $15.1 Million	-178,695 Reduced 18.95%	764,461 $55.4 Million
Q2 2021 Aug 16, 2021	BUY	$47.86 - $83.95 $19.8 Million - $34.7 Million	413,106 Added 77.94%	943,156 $79.2 Million
Q1 2021 May 17, 2021	BUY	$44.38 - $63.97 $3.35 Million - $4.83 Million	75,500 Added 16.61%	530,050 $25.7 Million
Q4 2020 Feb 16, 2021	BUY	$32.94 - $47.15 $15 Million - $21.4 Million	454,550 New	454,550 $21.4 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $77.3M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Octagon Capital Advisors LP with notifications on news.